Roche announced it would expand its collaboration with SQZ Biotechnologies into cell therapy applications by offering a new upfront investment of up to $ 125 m . The deal also includes clinical , regulatory and regulatory milestones worth a potential $ 250 m , while development milestones could cost the company more than $ 1 billion . The announcement includes a similar agreement struck between the two companies in 2015 , worth more than $ 500 million in combined incentives , and comes not long after hp secured $ 72 million in Series C financing in August from new investors including Everblue , Illumina Ventures and Invus .
Roche announced it will expand its collaboration with SQZ Biotechnologies into cell therapy development by offering a new upfront investment of up to $125m. The deal also includes clinical, regulatory and sales milestones worth a potential $250m, while development milestones could land the company more than $1 billion. The announcement follows a similar agreement struck between the two companies in 2015, worth more than $500m in combined incentives, and comes not long after SQZ secured $72m in Series C financing in August from new investors including Everblue, Illumina Ventures and Invus.